Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02810873 | Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer | terminated | N/A | 19 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 4, 2025 | clinicaltrials |
| NCT03054025 | Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors | terminated | N/A | 22 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 |
| Apr 29, 2025 |
| clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04533373 | Sensory Restoration After DIEP Flap Neurotization | terminated | N/A | 156 | Johns Hopkins UniversityOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04965688 | Biology Guided Therapy for Breast Cancer for ER Positive(SPOCK) | terminated | Phase 2 | 2 | Inova Health Care ServicesOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05867667 | Cardiac Rehabilitation to Improve Breast Cancer Outcomes(CRIBCO) | terminated | N/A | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04067544 | Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women | terminated | N/A | 3 | University of UtahOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | terminated | Phase 2 | 9 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 24, 2025 | clinicaltrials |
| NCT01315106 | High Resolution 3D Diffusion-weighted Breast MRI | terminated | — | 50 | Stanford UniversityOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Valerio TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | terminated | Phase 1 | 31 | Turnstone Biologics, Corp.INDUSTRY | 2 | Mar 10, 2025 | clinicaltrials |
| NCT03936933 | Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer | terminated | Phase 3 | 6 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04142476 | Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer(HORMONOVILLE) | terminated | N/A | 105 | Centre Georges Francois LeclercOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03941639 | Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment | terminated | — | 95 | Chinese University of Hong KongOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05080842 | A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | terminated | Phase 1 | 21 | Accutar Biotechnology IncINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT06390241 | Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer(ARTHE) | terminated | Phase 1 | 18 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05825768 | Preoperative Magnetic Resonance Imaging to Obtain Adequate Resection Margins in Breast Conserving Surgery, (PRIMAR) Trial(PRIMAR) | terminated | N/A | 227 | Aarhus University HospitalOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | terminated | Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03779867 | Acute Exercise Intervention in Breast Cancer Survivors(ACE) | terminated | N/A | 112 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03609021 | Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502 | terminated | — | 18 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 16, 2025 | clinicaltrials |
| NCT04440982 | Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients | terminated | Phase 2 | 98 | Lumicell, Inc.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03092635 | AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy | terminated | Phase 1 | 9 | Medical University of South CarolinaOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04256941 | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT01897441 | Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer | terminated | N/A | 31 | Albert Einstein College of MedicineOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT05176080 | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT03623945 | Autoantibodies in Breast Cancer Detection(ABCD) | terminated | — | 1,279 | Sanford HealthOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04675827 | De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade(Decrescendo) | terminated | Phase 2 | 139 | Jules Bordet InstituteOTHER | 6 | Dec 4, 2024 | clinicaltrials |
| NCT05395936 | Mastectomy Flap Temperature Study | terminated | N/A | 19 | Wake Forest University Health SciencesOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04657679 | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts(LEANORA) | terminated | Phase 4 | 21 | Georgetown UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | terminated | Early Phase 1 | 95 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Nov 22, 2024 | clinicaltrials |
| NCT02317783 | Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment | terminated | Phase 2 | 15 | University of UtahOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | terminated | Phase 2 | 1 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04060862 | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer(IPATunity150) | terminated | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 8 | Nov 8, 2024 | clinicaltrials |
| NCT05592483 | An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer(DB RESPOND) | terminated | — | 78 | AstraZenecaINDUSTRY | 9 | Nov 7, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT04899349 | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant(EPIK-B4) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2024 | clinicaltrials |
| NCT01127971 | Patient Registry: Partial Breast Irradiation(PBI Registry) | terminated | — | 145 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05650086 | Novel Thermal Imaging Technique for Breast Screening | terminated | — | 115 | University of ArizonaOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02681523 | ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.(ALERT) | terminated | Phase 2 | 8 | Imperial College LondonOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03043794 | Study of Stereotactic Radiotherapy for Breast Cancer | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04950010 | High-intensity Exercise After Treatment(HEAT) | terminated | N/A | 7 | University of NebraskaOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03284723 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | terminated | Phase 1 | 95 | PfizerINDUSTRY | 6 | Sep 3, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2025source: clinicaltrials